Last reviewed · How we verify
NCT00696592: ARMAST
Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-related Macular Degeneration
Phase 2 trial testing Bevacizumab (Avastin), Verteporfin (Visudyne) in Neovascular Age-related Macular Degeneration. Withdrawn.
31 January 2008
Quick facts
| Lead sponsor | University of Padova |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Start date | 31 January 2007 |
| Primary completion | 31 January 2008 |
| Estimated completion | 31 January 2008 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Bevacizumab (Avastin), Verteporfin (Visudyne) — full drug profile →
Conditions studied
- Neovascular Age-related Macular Degeneration — all drugs for Neovascular Age-related Macular Degeneration →
Sponsor
University of Padova
Who can join
Adults 55 to 80, any sex, with Neovascular Age-related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase II study was designed to evaluate the safety, tolerability, and efficacy of bevacizumab treatment in conjunction with PDT at the low fluence rate compared with bevacizumab alone or combined with PDT at the standard fluence rate, in patients with all types of choroidal neovascularization secondary to AMD. Hypothesis: bevacizumab in combination with PDT (low and standard fluence rate) will i) delay time to retreatment, ii) reduce the average number of treatments required compared to bevacizumab alone and iii) at low PDT fluence rate will improve long-term safety profile.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, et al · · 2014 · cited 181× · PMID 25170575 · DOI 10.1002/14651858.cd005139.pub3
Verify or expand the search:
- PubMed search for NCT00696592
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neovascular Age-related Macular Degeneration
Currently open trials in the same condition.
- NCT07275840 — A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD · Phase 2 · recruiting
- NCT06847542 — A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD · Phase 3 · recruiting
- NCT07053358 — Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients · EARLY_PHASE1 · recruiting
- NCT06680817 — A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) · recruiting
- NCT06495918 — Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- R · Phase 3 · active not recruiting
Other University of Padova trials
Trials by the same sponsor.
- NCT07435064 — NURsing-led FRAILty Prevention and Care · NA · not yet recruiting
- NCT07283354 — Comparison of Acceleromyography and Electromyography in Obese Patients Undergoing General Anesthesia · not yet recruiting
- NCT07259460 — Effects of Dexmedetomidine Target Controlled Infusion on Patient State Index Values and Electroencephalographic Spectrum · recruiting
- NCT07385118 — Daily Fluctuations in Brain-Derived Neurotrophic Factor and Cognition: Effects of Vigorous Exercise · NA · completed
- NCT07259291 — Minto and Eleveld Remifentanil Target Controlled Infusion (TCI) Models: a Clinical Comparison · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00696592 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Padova
- Last refreshed: 24 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00696592.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing